Website
http://dataportal.arc.gov.au/NCGP/API/grants/DP0662817
Funding Status
Closed
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Funded Activity Summary
Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.Funded Activity Details
Start Date: 03-2006
End Date: 12-2009
Funding Scheme: Discovery Projects
Funding Amount: $270,000.00
Funder: Australian Research Council
Research Topics
ANZSRC Field of Research (FoR)
Bioinorganic Chemistry | Inorganic Chemistry |
ANZSRC Socio-Economic Objective (SEO)
Treatments (e.g. chemicals, antibiotics) | Chemical sciences
